Keyword: Vertex Pharmaceuticals
Gilead's clinical director joins Nimbus to lead discovery; Immunocore’s CMO jumps to Tmunity; Kite taps Eisai vet to lead CAR-T sales.
Syntimmune has named Vertex’s Mario Saltarelli as chief medical officer, following several leadership changes at the company over the past 18 months.
The action prompted Galapagos to review the future of its relationship with AbbVie—and provided a boost to cystic fibrosis rival Vertex.
Vertex's newly expanded site covers 170,000 square feet, boosting Vertex’s ability to hunt for the next generation of blockbusters.
Shares in CRISPR fell 15% as investors digested the delay to the start of the gene-editing startup’s first U.S. clinical trial.
Vertex says its long-acting version of Kalydeco has been held up by an FDA data request—but analysts think it could be a bigger issue for its rivals.
Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.
The first trial of Translate Bio's nebulized messenger RNA therapy is now due to start in mid-2018, with results due a year later.
The financing tees up Enterprise to take three projects into the clinic and push one of them through a midphase proof-of-concept trial.
Gilead’s director of oncology clinical research jumps to Compugen, longtime Teva exec becomes Dr. Reddy's COO, Astellas names new ethics & compliance head.